Table 1 Baseline cohort characteristics by endophenotype in the UK Biobank
From: Endophenotype effect sizes support variant pathogenicity in monogenic disease susceptibility genes
Characteristic | LDL-C (mg/dL) | QTc (ms) | HbA1c (%) |
|---|---|---|---|
Participants with a measurable endophenotype, n | 189,652 | 33,520 | 189,741 |
Median endophenotype value (Q1–Q3) | 136 (114–159) | 411 (396–426) | 5.4 (5.1–5.6) |
Male, n (%) | 85,197 (44.9) | 16,582 (49.5) | 85,210 (44.9) |
European ancestry, n (%) | 165,783 (87.4) | 28,249 (84.3) | 166,335 (87.7) |
Mean age, years (SD) | 57.0 (8.1) | 52.6 (5.7) | 57.0 (8.1) |
Myocardial infarction, n (%) | 2995 (1.6) | 483 (1.4) | - |
Statin usage, n (%) | 31,909 (16.8) | - | - |
Median high-density lipoprotein, mg/dL (Q1–Q3) | 56.0 (46.3–64.0) | - | - |
Heart failure, n (%) | - | 74 (0.2) | - |
Beta blocker usage, n (%) | - | 1701 (5.1) | - |
Calcium channel blocker usage, n (%) | - | 2455 (7.3) | - |
Type 2 diabetes medication usage, n (%) | - | - | 7090 (3.7) |
Mean corpuscular volume, femtoliters (SD) | - | - | 91.2 (4.5) |
